Digest Network Come funziona
Network
/
Società
Ve
Non verificato

Verastem Oncology

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

90 comunicati stampa

Guarda tutti i comunicati
22/10/2026
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
14/10/2026
Oncologia
Salute
Attrezzature medico-sanitarie
Medicina - Varie
Farmaceutica
Biotecnologia
Finanza
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
14/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato del lavoro
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
14/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Web e Social Network
Eventi
Industria
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
05/10/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
02/10/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
28/09/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
24/09/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
08/09/2026
Web e Social Network
Industria
Eventi
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
02/09/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Verastem Oncology to Participate in Upcoming September Investor Conferences
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0